| Induction of apoptosis in resistant glioma cells by synthetic caspase-activation. | |
| | |
MedLine Citation:
|
PMID: 15015772 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The detailed mechanisms behind the resistance of malignant gliomas to therapy are not known. Inherent resistance to apoptosis is, however, one plausible explanation. In the present study we tried to delineate the molecular defects and to induce apoptosis by inducible caspases in three apparently apoptosis resistant glioma cell lines. U-105 MG, U-251 MG, and SF-767 were resistant to Fas-induced apoptosis as shown by the lack of Fas-induced cell death, morphological changes, annexin-V reactivity, Parp cleavage, caspase-3 cleavage, and caspase-3 activation. The glioma cells showed no consistent down-regulation of the pro-apoptotic proteins Fas, Fadd, caspase-3, caspase-8, caspase-9, Apaf-1, Bid, Bad, or Bax, and no consistent up-regulation of the anti-apoptotic proteins Bcl-x or Bcl-2. In U-105 MG, Fas was, however, not detected at the cell surface indicating intracellular retention. To assess if the apoptotic blocks could be by-passed, we introduced the so-called artificial death switches, i.e., inducible caspases and Fadd, into the glioma cells. Synthetic activation of inducible caspase-3, but not of caspase-8, resulted in apoptosis in the three glioma cell lines and inducible Fadd induced apoptosis in SF-767. The results were consistent with a block in the apoptotic signaling pathways of glioma cells between caspase-8 and caspase-3 activation, and that inducible Fadd could induce caspase-8 independent apoptosis in some cells. Apparently resistant glioma cells could thus be induced to undergo apoptosis by activation of appropriate death switches. This might have implications for the design of future therapeutic strategies. |
| | |
Authors:
|
Terese Karlsson; Roger Henriksson; Håkan Hedman |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of neuro-oncology Volume: 66 ISSN: 0167-594X ISO Abbreviation: J. Neurooncol. Publication Date: 2004 Jan |
Date Detail:
|
Created Date: 2004-03-12 Completed Date: 2004-04-01 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 8309335 Medline TA: J Neurooncol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 71-9 Citation Subset: IM |
Affiliation:
|
Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antigens, CD95
/
pharmacology Apoptosis* / drug effects Arabidopsis Proteins / metabolism Caspase 3 Caspase 8 Caspases / metabolism* Drug Resistance, Neoplasm Enzyme Activation Fatty Acid Desaturases / metabolism Glioma / enzymology, metabolism, pathology, physiopathology* Humans Jurkat Cells Neoplasm Proteins / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD95; 0/Arabidopsis Proteins; 0/Neoplasm Proteins; EC 1.14.19.-/Fatty Acid Desaturases; EC 1.14.99.-/Fad7 protein, Arabidopsis; EC 3.4.22.-/CASP3 protein, human; EC 3.4.22.-/CASP8 protein, human; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspase 8; EC 3.4.22.-/Caspases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vinc...
Next Document: Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents.